Experts explain who benefits from belantamab in relapsed myeloma and how REMS eye exams and dose tweaks keep treatment on track.
Delivering Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma Discussing Patient Selection, Ocular Monitoring, and Multidisciplinary Workflow
DREAMM-7 reveals belantamab combo extends myeloma PFS, with reversible eye effects, REMS monitoring, and fewer severe infections.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma
5